.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
McKesson
Queensland Health
US Department of Justice
Deloitte
Fuji
Harvard Business School
Mallinckrodt
Express Scripts
Medtronic

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 3,852,446

« Back to Dashboard

Details for Patent: 3,852,446

Title: ORGANIC COMPOUNDS IN TREATMENT OF PSYCHOTIC DISTURBANCES
Abstract:This invention concerns the use of the compound 2-nitro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]-thiazepine, as a neuroleptic agent.
Inventor(s): Schmutz; Jean (Muri Near Berne, CH), Hunziker; Fritz (Berne, CH)
Assignee: Sandoz, Inc. (Hanover, NJ)
Filing Date:Mar 19, 1973
Application Number:05/342,399
Claims:1. A pharmaceutical composition in the form of a tablet, capsule or dragee useful in treating psychotic disturbances in animals comprising as active ingredient, a therapeutically effective amount of 2-nitro-11-(4-methyl-1-piperazinyl)dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutical carrier or diluent.

2. A pharmaceutical composition in the form of a tablet, capsule or dragee useful in treating psychotic disturbances in animals according to claim 1, wherein the active ingredient is present in said composition in an amount sufficient to provide a daily dosage of from about 1 milligram to about 50 milligrams of the active ingredient.

3. A pharmaceutical composition in the form of a tablet, capsule or dragee useful in treating psychotic disturbances in animals according to claim 2, in unit dosage form, wherein the amount of active ingredient is from about 0.25 milligrams to about 25 milligrams.

4. A method of treating psychotic disturbances in animals, which comprises administering to an animal in need of said treatment a therapeutically effective amount of 2-nitro-11-(4-methyl-1-piperazinyl)-dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof.

5. A method according to claim 4, which comprises administering to the animal a daily dosage of from about 0.01 to about 2 mg per kilogram animal body weight of 2-nitro-11-(4-methyl-1-piperazinyl)-dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof.

6. A method according to claim 5, which comprises administering to the animal a daily dosage of from about 1 mg to about 50 mg of 2 nitro-11-(4-methyl-1-piperazinyl)dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof.

7. A method according to claim 6, wherein the daily dosage is given in divided doses 2 to 4 times a day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
McKesson
Argus Health
Chubb
Cipla
QuintilesIMS
Medtronic
Mallinckrodt
Harvard Business School
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot